Another odd-lot tender has appeared. This one has excellent mechanics and rather less exciting math.
Utah Medical Products, Inc. (NASDAQ: UTMD) announced that it intends to repurchase up to 650,000 shares at $75 per share, representing roughly 20% of the company’s outstanding stock. If the offer is oversubscribed, shareholders owning fewer than 100 shares who tender all of them are supposed to receive priority over everyone else.
That is exactly the provision we look for in an odd-lot tender.
The problem is that the market noticed too.
UTMD closed September 15 at $74.63. At that price, buying 99 shares and tendering them at $75 would generate a grand total of $36.63 in gross profit.
The odd-lot privilege is valuable. The spread, at least for now, is barely there.
The Utah Medical Products Tender
UTMD announced the proposed self-tender on September 15. The company intends to purchase up to 650,000 shares at a fixed price of $75 per share.
According to the company’s announcement:
- Maximum shares to be purchased: 650,000
- Purchase price: $75.00 per share
- Approximate percentage of outstanding shares: 20%
- Odd-lot priority: holders of fewer than 100 shares who tender all of them
- Proration: applies to other shareholders if the offer is oversubscribed
- Minimum tender condition: none
UTMD also reserves the right to purchase more than 650,000 shares.
The company’s announcement can be read here.
There is an important caveat: this is still a pre-commencement announcement. The formal Offer to Purchase and related SEC filings have not yet been filed. Anyone considering participating should read those documents once they are available.
The Odd-Lot Provision
If more than 650,000 shares are tendered, UTMD says it will first purchase shares from shareholders who own fewer than 100 shares and tender all of those shares. Remaining accepted shares would then be purchased from other shareholders on a pro rata basis.
In other words, 99 shares can once again be more useful than 100.
A holder of 99 shares who meets the final odd-lot requirements may be able to avoid proration entirely. A holder of 100 shares joins the ordinary pool.
This is the same basic structural advantage we have been tracking in our September odd-lot tender portfolio.
But guaranteed—or preferential—acceptance only helps if there is enough spread between the price you pay and the tender price.
99 Shares at $74.63
UTMD closed September 15 at $74.63 after the tender announcement pushed the shares sharply higher.
Using that price as our paper-portfolio reference:
| Amount | |
|---|---|
| Shares | 99 |
| Reference purchase price | $74.63 |
| Hypothetical cost | $7,388.37 |
| Tender price | $75.00 |
| Tender proceeds | $7,425.00 |
| Gross profit | $36.63 |
| Gross return | about 0.50% |
That is not much room for error.
A $25 corporate-action fee would consume most of the profit. A $38 fee would consume all of it. Even with a broker that charges no tender fee, the return has to compensate for the risk that the transaction changes, is delayed, or that the shares are not tendered correctly.
The economics improve if UTMD falls farther below $75 before the offer expires. At $73, for example, 99 shares would produce $198 of gross spread, or about 2.7%. At $70, the gross spread would be $495, or about 7.1%.
At $74.63, however, the market has already captured nearly all of the tender premium.
This Is Very Different From Computer Modelling Group
Our recent Computer Modelling Group odd-lot tender started with a much healthier spread.
CMG was trading at C$3.80 while the bottom of its tender range was C$4.00. Even if its Dutch auction cleared at the lowest possible price, our 99-share paper position began with roughly a 5.3% gross spread.
UTMD is almost the inverse situation. The odd-lot protection is cleaner, the tender price is fixed, and there is no auction-price uncertainty. But the stock has already moved so close to $75 that the potential profit is minimal.
It is a useful reminder that an odd-lot preference is not itself the opportunity. It merely improves the mechanics of an opportunity that still needs an attractive price.
UTMD Can Afford a Large Buyback
The tender is more interesting when viewed as a capital-allocation decision.
UTMD reported $87.5 million of cash and investments and no debt as of June 30, 2026. The company had approximately 3.18 million shares outstanding in August.
Buying 650,000 shares at $75 would cost $48.75 million before transaction expenses and would retire roughly one-fifth of the company.
That is a meaningful repurchase rather than financial housekeeping.
UTMD’s latest quarterly filing said management intended to use cash not needed for operations for acquisitions, investment in the business, dividends or repurchases when management believed the stock was undervalued.
The balance-sheet number should not be treated as a current post-tender cash forecast. UTMD subsequently acquired Orion Medical Supplies in the United Kingdom, and the tender itself has not yet been completed. But the June balance sheet helps explain why the board can contemplate buying such a large percentage of the outstanding shares.
The Business Has Not Been Growing
There is another reason not to treat the tender as free money for continuing shareholders.
UTMD’s revenue declined 12.3% in the first half of 2026 compared with the first half of 2025. Second-quarter revenue declined 14.3%. First-half net income was $5.29 million, down from $6.09 million a year earlier.
A large reduction in the share count can improve earnings per share if the underlying earnings hold up. It cannot by itself fix declining sales.
For long-term holders, that is the more interesting question: is UTMD intelligently buying a temporarily undervalued business, or using excess cash to shrink the denominator while the numerator is under pressure?
The tender gives management a chance to retire approximately 20% of the stock. Whether that creates lasting value depends on what the remaining business earns.
There Is a Date Problem We Need the Formal Documents to Resolve
UTMD’s September 15 announcement contains an odd timing detail.
The release says the offer is expected to commence September 22, or as soon as possible thereafter, and expire 15 business days later. It also says shareholders may tender shares on or before October 7.
Those statements do not line up neatly on the calendar.
I would therefore treat October 7 as preliminary rather than assume it is the operative broker deadline. Once UTMD files the Offer to Purchase with the SEC, that document should give us the definitive expiration time, withdrawal rights and other conditions. Brokers can also impose their own earlier corporate-action deadlines.
What We Still Need From the Tender Documents
Before treating this as an actionable odd-lot trade, I want to confirm several details in the formal filing:
- The exact definition of an eligible odd-lot holder
- The final expiration date and time
- Any broker or registered-holder requirements
- Withdrawal rights
- Conditions allowing UTMD to amend or terminate the offer
- Tax treatment described by the company
- Whether any procedural detail changes the announced odd-lot priority
The press release is encouraging on all of the important structural points, but a press release is not the tender document.
Our UTMD Paper Trade
For purposes of our continuing odd-lot experiment, I am adding UTMD to the watch list using the September 15 closing price as the reference point.
Security: Utah Medical Products, Inc. (NASDAQ: UTMD)
Reference date: September 15, 2026 close
Reference price: $74.63
Hypothetical shares: 99
Hypothetical cost: $7,388.37
Tender price: $75.00
Gross potential profit: $36.63
Gross potential return: approximately 0.50%
Odd-lot provision: announced priority for shareholders owning fewer than 100 shares who tender all shares
Preliminary deadline: October 7, subject to confirmation in the formal tender documents
I am recording the trade because it fits the experiment. I would not confuse that with saying the spread is attractive at $74.63.
If the stock price falls while the $75 tender remains intact, the opportunity could become much more interesting. If it remains pinned just below $75, UTMD may end up being a useful case study in an odd-lot advantage that the market priced away before we could do much with it.